WCN26-3605 NOVEL INSIGHTS INTO PHARMACOKINETICS OF INTRAPERITONEAL CEFEPIME DURING AUTOMATED PERITONEAL DIALYSIS USING MONTE CARLO SIMULATIONS

The International Society for Peritoneal Dialysis (ISPD) guidelines currently recommend intraperitoneal (IP) administration of cefepime, a fourth-generation cephalosporin, as a first-line monotherapy for infectious peritoneal dialysis-associated peritonitis (PDAP). Despite this, data on the pharmacokinetics (PK) of cefepime and its optimal dosing in automated peritoneal dialysis (APD) remain limited. This study aimed to characterize the PK of cefepime in APD patients and to predict the probability of achieving pharmacokinetic/pharmacodynamic (PK/PD) targets during short versus long-dwell periods using Monte Carlo simulations.